FDA seeks with­draw­al of heart­burn drugs due to new car­cino­gen con­cerns

6 years ago
FDA+

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

6 years ago
Coronavirus

‘There was a grow­ing weari­ness’: Rush­ing against a pan­dem­ic clock, As­pen Neu­ro­science se­cures $70M Se­ries A

6 years ago
Financing

Flex­ion se­cures Chi­na deal for os­teoarthri­tis drug; Strug­gling to find a buy­er, Ako­rn throws in the tow­el

6 years ago
News Briefing

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

6 years ago
Cell/Gene Tx
FDA+

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

6 years ago
Coronavirus

ITeos nabs $125M as they prep Keytru­da com­bi­na­tion tri­al — if Covid-19 will let them

6 years ago
Financing
R&D

Dai­ichi Sankyo sinks $200M in­to new gene ther­a­py tech from Ul­tragenyx

6 years ago
Deals
Cell/Gene Tx

Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

6 years ago
FDA+
Coronavirus

Mo­tion de­nied: Gilead still on the hook for $1.5B in dam­ages over CAR-T patent dis­pute with Bris­tol My­ers Squibb

6 years ago
People
Cell/Gene Tx

A quiver of ar­rows for im­mune dis­or­ders: Pan­dion scores $80M in fresh fund­ing

6 years ago
Financing
Startups

It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

6 years ago
R&D
Coronavirus

My­ovant grabs $40M up­front in re­gion­al deal for re­l­u­golix; Akero an­nounces NASH suc­cess but Covid-19 de­lays

6 years ago
News Briefing

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

6 years ago
FDA+

Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

6 years ago
R&D

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

6 years ago
Financing
R&D

Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

6 years ago
R&D
China

Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

6 years ago
Financing

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic ...

6 years ago
Coronavirus

Eli Lil­ly antes up $60M gam­ble on a dis­cov­ery deal with GSK-backed biotech

6 years ago
Deals

Un­fazed by dis­rup­tions, Cowen's in­vest­ment arm backs AM-Phar­ma's $176M piv­otal plan around lethal con­di­tion

6 years ago
Financing

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

6 years ago
R&D

Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative ...

6 years ago
R&D
Coronavirus

As­traZeneca ex­pands deal with Imag­inAb; Ovid posts promis­ing da­ta on Take­da-part­nered seizure drug

6 years ago
News Briefing
First page Previous page 848849850851852853854 Next page Last page
A service from the Financial Times